Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic has maintained a Buy rating on Boston Scientific (NYSE:BSX) and increased the price target from $60 to $64.
November 27, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst reaffirms a Buy rating on Boston Scientific and raises the price target to $64, indicating a positive outlook on the stock.
The increase in price target by Canaccord Genuity suggests a bullish outlook on Boston Scientific, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100